[
  {
    "ts": null,
    "headline": "Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'",
    "summary": "In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market’s irrationality. What Happened: Cramer made a case last week, asserting that the current market conditions are far removed from the dotcom bubble burst of the late 90s. He emphasized that despite the froth, today’s market is more rational. Cramer drew attention to the irrationality in recent IPOs like Circle, Figma, an",
    "url": "https://finnhub.io/api/news?id=9359eac666f9082521b2255f57c269f4b79a3ce2091fef59626199f6f2478e63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755362783,
      "headline": "Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'",
      "id": 136379674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market’s irrationality. What Happened: Cramer made a case last week, asserting that the current market conditions are far removed from the dotcom bubble burst of the late 90s. He emphasized that despite the froth, today’s market is more rational. Cramer drew attention to the irrationality in recent IPOs like Circle, Figma, an",
      "url": "https://finnhub.io/api/news?id=9359eac666f9082521b2255f57c269f4b79a3ce2091fef59626199f6f2478e63"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead",
    "summary": "Eli Lilly (LLY) & Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.",
    "url": "https://finnhub.io/api/news?id=7b630d8d0032d4e673befb0a12521684b75b08b4922b53309f0db53169873e5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755334833,
      "headline": "Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead",
      "id": 136378063,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178382825/image_2178382825.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly (LLY) & Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.",
      "url": "https://finnhub.io/api/news?id=7b630d8d0032d4e673befb0a12521684b75b08b4922b53309f0db53169873e5d"
    }
  },
  {
    "ts": null,
    "headline": "THQ: 13.3% Top Contrarian Healthcare Yield, Discounted Price",
    "summary": "abrdn Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.",
    "url": "https://finnhub.io/api/news?id=fc0569d55a8052f5109061e7b8b15dae72545fdc59bb890d6fab25ff0c0ab357",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755331200,
      "headline": "THQ: 13.3% Top Contrarian Healthcare Yield, Discounted Price",
      "id": 136377544,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205706076/image_2205706076.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "abrdn Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.",
      "url": "https://finnhub.io/api/news?id=fc0569d55a8052f5109061e7b8b15dae72545fdc59bb890d6fab25ff0c0ab357"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Slashes PT on Eli Lilly and Company (LLY) to $825 From $975",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $825 from $975, keeping an Overweight rating on the shares. The firm told investors that it believes that the […]",
    "url": "https://finnhub.io/api/news?id=a9d0e1471f844ec615b52dab68ebfeaf55b0e9914082c8baebdc99d631c9424f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755308623,
      "headline": "Cantor Fitzgerald Slashes PT on Eli Lilly and Company (LLY) to $825 From $975",
      "id": 136376138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $825 from $975, keeping an Overweight rating on the shares. The firm told investors that it believes that the […]",
      "url": "https://finnhub.io/api/news?id=a9d0e1471f844ec615b52dab68ebfeaf55b0e9914082c8baebdc99d631c9424f"
    }
  }
]